QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Clinical trial NCT07716449 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07716449
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2026-08-01
Primary completion: 2028-09-01
Enrollment: 560

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.